Skip to main content

Axsome Therapeutics, Inc. (AXSM)

NASDAQ: AXSM · IEX Real-Time Price · USD
-0.33 (-0.82%)
After-hours:Oct 22, 2021 7:59 PM EDT
-0.72 (-1.76%)
At close: Oct 22, 4:00 PM
Market Cap1.51B
Revenue (ttm)n/a
Net Income (ttm)-113.63M
Shares Out37.60M
EPS (ttm)-3.04
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close40.82
Day's Range38.62 - 40.72
52-Week Range19.38 - 87.24
AnalystsStrong Buy
Price Target86.21 (+115.0%)
Est. Earnings DateNov 4, 2021

About AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 ...

IPO DateNov 19, 2015
CEOHerriot Tabuteau
Stock ExchangeNASDAQ
Ticker SymbolAXSM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price forecast is 86.21, which is an increase of 114.99% from the latest price.

Price Target
(114.99% upside)
Analyst Consensus: Strong Buy


Axsome Therapeutics to Report Third Quarter 2021 Financial Results on November 8, 2021

Axsome to host conference call and webcast on Monday, November 8, 2021 at 8:00 AM Eastern Time

3 days ago - GlobeNewsWire

What's Happening With Axsome Therapeutics Stock?

Last month we discussed that Axsome Therapeutics stock is likely to continue to see higher levels after it rose 6% in a week following the U.S. FDA's acceptance of a new drug application for the company...

5 days ago - Forbes

Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million

$100 million now available upon the potential FDA approval of AXS-05

5 days ago - GlobeNewsWire

3 Biotech Stocks That Could Rise 90% or More, According to Wall Street

These stocks are expected to put up big gains in a short amount of time.

Other symbols:CCXIOCUL
6 days ago - The Motley Fool

Why Axsome Therapeutics Stock Rocketed Higher This Week

Optimism among investors is growing for the possible approval of the biotech's MDD drug.

1 week ago - The Motley Fool

1 Beaten-Down Stock With 10X Potential

This biotech is down, but it isn't out just yet.

1 week ago - The Motley Fool

Why Axsome Therapeutics Stock Caught Fire in September

This beaten-down biotech regained some lost ground last month.

2 weeks ago - The Motley Fool

SHAREHOLDER ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses Over $...

NEW YORK, Sept. 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Axsome Therapeutics, In...

3 weeks ago - PRNewsWire

2 Best Biotech Stocks to Buy Right Now

Aurinia Pharmaceuticals and Axsome Therapeutics are two names that growth investors should have on their radars right now.

Other symbols:AUPH
4 weeks ago - The Motley Fool

Do Options Traders Know Something About Axsome (AXSM) Stock We Don't?

Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.

4 weeks ago - Zacks Investment Research

Why Wall Street Thinks This Biotech Stock Can Triple Your Money

The risks are huge, but so are the potential returns.

1 month ago - The Motley Fool

Axsome Therapeutics Stock Rises 36% In A Month But Will The Rally Continue?

A couple of months back we discussed that Axsome Therapeutics stock is likely to rebound after it fell nearly 20% in a month following the U.S. FDA's decision to pull the breakthrough therapy designatio...

1 month ago - Forbes

Axsome (AXSM) Begins Late-Stage Sleep Disorder Study on AXS-12

Axsome (AXSM) is developing AXS-12 as a potential treatment for narcolepsy. The company initiates enrollment in a phase III study evaluating AXS-12.

1 month ago - Zacks Investment Research

Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy

NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders...

1 month ago - GlobeNewsWire

Axsome's (AXSM) Migraine Drug AXS-07 NDA Gets FDA Acceptance

Axsome (AXSM) is seeking approval for its key pipeline candidate, AXS-07, as a potential acute treatment for migraine.

1 month ago - Zacks Investment Research

Axsome Therapeutics Inc Ranked Among Today's Top Shorts After The European Central Bank Says It May Slow Down Bond Pu...

The Dow Jones dipped about 40 points, the S&P 500 was flat, and the Nasdaq saw some mild gains, led by Big Tech stocks such as Apple, Facebook, and Amazon. Find opportunities in today's market with the ...

1 month ago - Forbes

Why Axsome Therapeutics Stock Cratered in August

An unexpected regulatory setback weighed heavily on the biotech's shares last month.

1 month ago - The Motley Fool

Axsome (AXSM) Up 11.7% Since Last Earnings Report: Can It Continue?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

3 Healthcare Stocks That Might Skyrocket When COVID Is Over

Stocks of biotech companies fighting COVID-19 have been great investments over the last two years. What stocks might zoom higher when the pandemic is over?

Other symbols:LUNGVRTX
1 month ago - The Motley Fool

3 Biotech Stocks Wall Street Expects to Double Soon

All three stocks on this list can more than double your money according to investment bank analysts who cover them.

Other symbols:CMPSZGNX
1 month ago - The Motley Fool

Buy, Sell, or Hold Axsome Therapeutics Stock After Its FDA Approval Delay?

There are still plenty of unknowns related to Axsome's FDA filing.

1 month ago - The Motley Fool

3 Biotech Stocks That Are Too Cheap to Ignore

You'll definitely want to check out these biotech bargains.

Other symbols:ABBVJAZZ
1 month ago - The Motley Fool

Here's Why Axsome Therapeutics Stock Is Surging Today

The company still doesn't have much to say about the FDA and its experimental new anti-depression drug.

1 month ago - The Motley Fool

Which Biotech Stock Will Shock the Market in 2022?

Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?

1 month ago - The Motley Fool

Axsome's (AXSM) Stock Up Despite FDA Delay on Depression Drug

FDA delays decision on Axsome Therapeutics' (AXSM) new drug application for AXS-05, a potential treatment for major depressive disorder.

1 month ago - Zacks Investment Research